Page 39 - Pharma Sector

Chintan shivir on drugs to diagnose and treat issues of trust, quality

Proposals to be discussed at Hyderabad conclave include having a centralised drug registration system under CDSCO

Former Ranbaxy, DRL exec Rajeev Raghuvanshi appointed as new DCGI

Appointment comes at a time when India's pharma regulatory landscape is under the scanner

Have to keep R&D spends at 12% of revenue: Biocon's Kiran Mazumdar-Shaw

It's a high growth phase for us in Biocon Biologics: We crossed the Rs 1,500-crore mark in revenue for the first time this quarter. We will exit this year (FY23) at Rs 2,000-crore level

Torrent Pharmaceuticals forays into OTC segment with calcium supplement

Torrent Pharmaceuticals on Tuesday said it has forayed into the over-the-counter segment in the country with Shelcal 500, a calcium supplement brand. With its composition of 500mg Calcium and 250 IU of Vitamin D3, Shelcal 500 helps optimise calcium absorption, increases bone density, improves muscle strength and helps boost immunity. The calcium is sourced from natural ingredients like oyster shell, having good absorption/bioavailability in the body. "With Shelcal's entry into OTC, the brand is poised to become the largest calcium supplement brand in India," Torrent Pharmaceuticals Director Aman Mehta said in a statement. According to studies, 40.6 per cent of Indians are calcium-deficient, while 79 per cent are Vitamin D-deficient.

Aurobindo Pharma's consolidated net profit down 18.7% at Rs 491 Cr in Q3

Aurobindo Pharma Limited on Thursday said its consolidated net profit for the quarter ended January 31 was down by 18.7 per cent to Rs 491.2 crore against Rs 604.3 crore in Q3FY22. A press release from the drug maker said revenue from operations during the quarter under discussion was up by 6.7 per cent to Rs 6,407.10 crore against Rs 6,002.2 in the same period last fiscal. Commenting on the company's performance, K Nithyananda Reddy, Vice-Chairman and Managing Director of the company said "We witnessed an improved momentum backed by recovery across our business verticals and our endeavor is to continuously innovate and differentiate." In line with the companys commitment to innovate, there is an increase in the investments in Biosimilars. The company aims to sustain the momentum with new launches, improved cost efficiencies and adherence to the highest standards of compliance, supported by strong execution, he further said. During the quarter, formulation revenue increase by 9.2

With focus on non-US geographies, Amneal Pharma eyes India market

The company is actively recruiting its field force, and aims to have 600-700 medical representatives by the end of 2023

Boosting pharma research

Govt should not solely depend on monetary incentives

CDSCO probes Indian eyedrops after US FDA flags contamination risk

Global Pharma has initiated a voluntary recall at the consumer level of all unexpired lots of EzriCare Artificial Tears and Delsam Pharma's Artificial Tears

On the agenda: Budget focuses on quality and reach of healthcare in India

It is hoped there is both a short- and long-term vision to make India a leader in the pharmaceutical sector beyond generic drug manufacture

Budget backs pharma R&D, nursing colleges, skilling in medical devices

A mission will be launched to eliminate sickle cell anaemia in the country by 2047, says Finance Minister

CRISIL SME Tracker: Strong domestic demand to drive pharma growth in FY23

In December, the domestic pharmaceuticals market grew 10.4 per cent on exceptional growth in both volume sales and prices

Strong US sales momentum may drive further gains for Zydus Lifesciences

Market share gains in the Indian market and margin expansion are other positives

Granules India ties up with Greenko Group for 'green' pharma zones

As a part of the partnership, Granules and Greenko ZeroC will develop and promote state-of-the-art Integrated Green Pharmaceutical Zones (GPZ) with first collaboration in Kakinada, Andhra Pradesh

Timely resolution of FDA action crucial to Indian pharma's US pipeline

Analysts say overall risks remain high for US generics business

Cough syrup deaths: Centre, UP team inspect pharma firm's Noida unit

Cough syrup maker linked to Uzbekistan deaths halts production; samples of Dok-1 Max sent for analysis

After Gambia, now Uzbekistan alleges Indian cold drug killed its children

Noida-based Marion Biotech's Dok-1 Max anti-cold medicine under scanner after the Central Asian nation blames it for 18 deaths

Bitter medicine for pharma regulation

The Gambian tragedy has raised uncomfortable questions about drug regulation in India. The Truth Pill is a depressing but eye-opening reality check of the regulatory landscape

Domestic, semi-regulated markets to drive pharmaceutical industry's growth

High raw material prices to put pressure on margins

CDSCO, states begin joint checks of drug-making units across India

Objective of drug regulation is to ensure safety, efficacy, and quality of drugs

WHO stands by action of issuing alert against Maiden Pharma cough syrup

Asserts that testing done in labs in Ghana and Switzerland confirmed excess levels of contaminated syrups that are "dangerous and should not be in any medicine, ever"